Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis

Background and Purpose-Treatment of cerebral sinus thrombosis with heparin is controversial. We conducted a double-blind, placebo-controlled multicent er trial to examine whether anticoagulant treatment improves outcome in pat ients with sinus thrombosis. Methods Patients were randomized between body weight-adjusted subcutaneous nadroparin (180 anti-factor Xa units/kg per 24 hours) and matching placebo for 3 weeks (double-blind part of trial), followed by 3 months of oral anti coagulants for patients allocated nadroparin (open part). Patients with cer ebral hemorrhage caused by sinus thrombosis were also included. Results-Sixty patients were enrolled, and none were lost to follow-up. In 1 patient the diagnosis proved wrong after randomization. After 3 weeks, 6 o f 30 patients (20%) in the nadroparin group and 7 of 29 patients (24%) in t he placebo group had a poor outcome, defined as death or Barthel Index scor e of <15 (risk difference, -4%; 95% CI, -25 to 17%; NS). After 12 weeks, 4 of 30 patients (13%) in the nadroparin group and 6 of 29 (21%) in the place bo group had a poor outcome, defined as death or Oxford Handicap Score of g reater than or equal to 3 (risk difference, -7%; 95% CI, -26% to 12%; NS). There were no new symptomatic cerebral hemorrhages. One patient in the nadr oparin group had a major gastrointestinal hemorrhage, and 1 patient in the placebo group died from clinically suspected pulmonary embolism. Conclusions Patients with cerebral sinus thrombosis treated with anticoagul ants (low-molecular-weight heparin followed by oral anticoagulation) had a favorable outcome more often than controls, but the difference was not stat istically significant. Anticoagulation proved to be safe, even in patients with cerebral hemorrhage.